You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 5, May 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Ophthalmology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS)

COMS Report No. 15

The Collaborative Ocular Melanoma Study Group

Arch Ophthalmol. 2001;119:670-676.

Background  A systematic review and assessment of disease-related mortality as part of standardized prospective patient follow-up and evaluation within a multicenter clinical trial have been lacking in previous studies of choroidal melanoma.

Objective  To describe disease status at death in patients with large choroidal melanoma treated and followed up in the Collaborative Ocular Melanoma Study (COMS).

Design  Analysis of reviews of patient status at death performed by the COMS Mortality Coding Committee using available clinical and histopathologic information.

Setting and Patients  Reviews of deaths as of July 31, 1997, the cutoff date for reporting initial mortality findings.

Interventions  Patients were treated by either enucleation preceded by external beam radiotherapy or enucleation only.

Main Outcome Measures  Disease status at the time of death and certainty associated with the coding of disease status, sites of metastasis, and availability of autopsy.

Results  Of 1003 patients enrolled in the trial, 457 had died; the estimated median survival from time of enrollment was 7.4 years. Disease status at time of death had been reviewed for 435 deaths (95%). The autopsy rate was 6%. A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sites were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis. The likelihood of 3 or more sites increased more than 4-fold when autopsy results were available.

Conclusions  Detailed mortality coding following a standard protocol provides the most accurate reporting to date of disease-related mortality in patients with choroidal melanoma and also identifies difficulties. Guidelines for the evaluation of future patients in clinical studies of choroidal melanoma are suggested.


Prepared by the COMS Mortality Coding Committee: James K.V. Willson, MD, Daniel M. Albert, MD, Marie Diener-West, PhD, Lee McCaffrey, MA, Claudia S. Moy, PhD, and Robert E. Scully, MD. A complete listing of the COMS Group was published previously (Control Clin Trials. 1993;14:352-391; Am J Ophthalmol. 1998;125:745-766).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(5):788-789.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term survival of uveal melanoma patients after surgery for liver metastases
Frenkel et al.
Br J Ophthalmol 2009;93:1042-1046.
ABSTRACT | FULL TEXT  

c-KIT in Uveal Melanoma: Big Fish or Red Herring?
Daniels and Abramson
Arch Ophthalmol 2009;127:695-697.
FULL TEXT  

CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation
Holfort et al.
Br J Ophthalmol 2009;93:641-644.
ABSTRACT | FULL TEXT  

PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro
Yang et al.
IOVS 2008;49:2518-2525.
ABSTRACT | FULL TEXT  

Resveratrol Inhibits Uveal Melanoma Tumor Growth via Early Mitochondrial Dysfunction
van Ginkel et al.
IOVS 2008;49:1299-1306.
ABSTRACT | FULL TEXT  

Differential Expression of Chemokine Receptors on Uveal Melanoma Cells and Their Metastases
Li et al.
IOVS 2008;49:636-643.
ABSTRACT | FULL TEXT  

Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern.
Lindegaard et al.
IOVS 2006;47:3268-3275.
ABSTRACT | FULL TEXT  

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
Peters et al.
Ann Oncol 2006;17:578-583.
ABSTRACT | FULL TEXT  

Characterization of Ocular and Metastatic Uveal Melanoma in an Animal Model
Blanco et al.
IOVS 2005;46:4376-4382.
ABSTRACT | FULL TEXT  

Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No. 26
Collaborative Ocular Melanoma Study Group*
Arch Ophthalmol 2005;123:1639-1643.
ABSTRACT | FULL TEXT  

Variates of Survival in Metastatic Uveal Melanoma
Rietschel et al.
JCO 2005;23:8076-8080.
ABSTRACT | FULL TEXT  

Whole body PET/CT for initial staging of choroidal melanoma
Finger et al.
Br J Ophthalmol 2005;89:1270-1274.
ABSTRACT | FULL TEXT  

Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy
Finger and Kurli
Br J Ophthalmol 2005;89:730-738.
ABSTRACT | FULL TEXT  

Second Primary Cancers After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: COMS Report No. 25
Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2005;123:601-604.
ABSTRACT | FULL TEXT  

Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23
Diener-West et al.
JCO 2004;22:2438-2444.
ABSTRACT | FULL TEXT  

Long-term Survival in a Patient With Uveal Melanoma and Liver Metastasis
Duh et al.
Arch Ophthalmol 2004;122:285-287.
FULL TEXT  

Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala et al.
IOVS 2003;44:4651-4659.
ABSTRACT | FULL TEXT  

Case 38-2002 - A 54-Year-Old Man with Hypercalcemia, Renal Dysfunction, and an Enlarged Liver
Erban and Tang
NEJM 2002;347:1952-1960.
FULL TEXT  

Imaging to Detect Metastases From Malignant Uveal Melanoma
Eskelin and Kivela
Arch Ophthalmol 2002;120:676-676.
FULL TEXT  

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings: COMS Report No. 18
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2001;119:969-982.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.